Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
09/21/2021 09/22/2021 09/23/2021 09/24/2021 09/27/2021 Date
339.35(c) 340.05(c) 342.6(c) 340.4(c) 337.55 Last
1 134 706 1 156 295 1 568 475 872 454 1 081 891 Volume
-0.63% +0.21% +0.75% -0.64% -0.84% Change
More quotes
Estimated financial data (e)
Sales 2021 61 371 M 66 291 M 66 291 M
Net income 2021 14 747 M 15 929 M 15 929 M
Net cash position 2021 4 290 M 4 634 M 4 634 M
P/E ratio 2021 19,8x
Yield 2021 2,76%
Sales 2022 62 028 M 67 000 M 67 000 M
Net income 2022 15 426 M 16 663 M 16 663 M
Net cash position 2022 11 414 M 12 329 M 12 329 M
P/E ratio 2022 19,0x
Yield 2022 2,86%
Capitalization 298 B 322 B 321 B
EV / Sales 2021 4,78x
EV / Sales 2022 4,61x
Nbr of Employees 101 465
Free-Float 83,5%
More Financials
Company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The... 
Sector
Pharmaceuticals
Calendar
09/28Presentation
More about the company
Ratings of Roche Holding AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about ROCHE HOLDING AG
07:19aGILEAD SCIENCES : Pfizer begins study of oral drug for prevention of COVID-19
RE
09/24ROCHE : Muscular Disease Therapies Show Efficacy In Various Studies
MT
09/24PRESS RELEASE : Roche presents new data at World -2-
DJ
09/24PRESS RELEASE : Roche presents new data at World Muscle Society (WMS) 2021 highlighting ne..
DJ
09/24ROCHE : presents new data at World Muscle Society (WMS) 2021 highlighting new advances for..
AQ
09/23ROCHE : WHO Recommends Roche-Regeneron COVID-19 Antibody Cocktail For High-Risk Patients
MT
09/23REGENERON PHARMACEUTICALS : WHO backs Regeneron COVID-19 drug cocktail as UN body calls fo..
RE
09/23ROCHE HOLDINGS AG : Credit Suisse gives a Neutral rating
MD
09/23ROCHE : Canadian Blood Services selects Roche Diagnostics Canada as a partner of choice fo..
AQ
09/22ROCHE : Joins CG Oncology to Study Novel Immunotherapy Combination in Cancer Patients
MT
09/22ROCHE : Rolls Out Three Respiratory Tests On Cobas 6800/8800 Systems
MT
09/22PRESS RELEASE : Roche launches three respiratory -2-
DJ
09/22ROCHE : launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to..
AQ
09/22PRESS RELEASE : Roche launches three respiratory test panels on cobas 6800/8800 Systems in..
DJ
09/22Roche Launches Three Respiratory Test Panels on Cobas 6800/8800 Systems in CE Markets t..
CI
More news
News in other languages on ROCHE HOLDING AG
09/25Pharmakonzern Roche feiert 125-Jahr-Jubiläum mit Lichtspektakel
09/24MERCK, ROCHE, SHIONOGI : la course aux traitements Covid sous forme de pilule
09/24PLANÈTE BOURSE : La revue de presse du vendredi 24 septembre 2021
09/24Les traitements de Roche contre les maladies musculaires se révèlent efficaces dans div..
09/24Roche kündigt neue Evrysdi- und SRP-9001-Daten für Fachkongress an
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | ROG | CH0012032048 | MarketScreener
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 340,40 CHF
Average target price 382,65 CHF
Spread / Average Target 12,4%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Technology Officer
Christoph Franz Chairman
Urs Jaisli Chief Compliance Officer
AndrÚ S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG10.16%321 605
JOHNSON & JOHNSON4.44%432 675
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037
ABBVIE INC.-0.07%189 211